Morphogenesis and Lacerta Named as Finalists for SEBIO Awards (SEBIO)
Two UF startups who have incubated at UF Innovate | Sid Martin Biotech have been named as finalists for the SEBIO awards. Sid Martin alum Morphogenesis is a finalist in Initial Venture Funding; Sid Martin resident client Lacerta Therapeutics is a finalist in the Strategic Investment category. Over the past two decades, the Southeast has […]
Sarepta Carries Lacerta Through $30M Round (Global University Venturing)
UF Innovate | Sid Martin Biotech resident client Lacerta Therapeutics, a US-based gene therapy startup of University of Florida, received $30m in funding from biopharmaceutical firm Sarepta Therapeutics. Founded in 2017, Lacerta Therapeutics is developing gene therapy programs for rare, inherited metabolic conditions, known as lysosomal storage disorders, such as Pompe disease and the fatal […]
UF Innovate | Sid Martin Biotech Resident Company Lacerta Therapeutics, Inc. Closes On $30 million Investment Round (Business Wire)
UF Innovate | Sid Martin Biotech, the leading biotechnology incubator at the University of Florida, announces resident company Lacerta Therapeutics, Inc., has closed on a $30 million investment round. UF startup Lacerta is a clinical-stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system […]
Gene Therapy Startup Lacerta Therapeutics Raises $30M in Equity Financing from Sarepta (MedCityNews)
A startup based out of the University of Florida developing viral vector-based gene therapies has drawn an equity investment from a larger, commercial-stage drugmaker. Lacerta Therapeutics closed on the $30 million investment round, made by Cambridge, Massachusetts-based Sarepta Therapeutics, which gives Sarepta rights to multiple Lacerta central nervous system gene therapy programs. The announcement came […]
Sarepta Dives Deeper into Gene Therapy (PharmaPhorum)
Sarepta Therapeutics has handed $30 million to UF startup and Sid Martin Biotech resident client Lacerta in exchange for a group of gene therapies, including a Pompe disease candidate. According to the agreement Sarepta will make an equity investment of $30 million in Lacerta Therapeutics gaining rights to two unnamed CNS-targeted gene therapy programs including […]